- Sanofi: Great Yield And Plenty Of Upside Potential
May 11, 2026 · seekingalpha.com
Sanofi (SNY) is rated a Strong BUY, with a robust pipeline, strong FCF, and a compelling turnaround under new leadership. SNY offers a 5.5%+ dividend yield, undervalued multiples, and projected 16–20% annualized total returns over the next five years. Recent product launches drove 14% of Q1 revenue, with 80 pipeline products and 23 in mid-to-late stage development supporting future growth.
- DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
May 8, 2026 · zacks.com
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
- Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports
May 6, 2026 · reuters.com
Sanofi has asked the U.S. Food and Drug Administration to pull its diabetes drug out of the regulator's new fast-track review program, STAT News reported on Wednesday.
- Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1
May 6, 2026 · prnewswire.com
The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification DURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation, today announced Sanofi as one of its inaugural industry sponsors.
- SANOFI SUPPORTS ALPHADETECT TO ACCELERATE DETECTION OF ALPHA-1
May 6, 2026
THE SPONSORSHIP HELPS EXPAND PROVEN ALPHA-1 DETECTION STRATEGIES, WHICH WILL ENABLE EARLIER PATIENT IDENTIFICATION DURHAM, N.C., MAY 6, 2026 /PRNEWSWIRE/ -- ALPHADETECT, THE NONPROFIT ORGANIZATION POWERED AND FUNDED BY THE ALPHA-1 FOUNDATION, TODAY ANNOUNCED SANOFI AS ONE OF ITS INAUGURAL INDUSTRY SPONSORS.
- Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?
Apr 30, 2026 · fool.com
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
- Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Apr 29, 2026 · globenewswire.com
Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on April 29, 2026, under the chairmanship of Frédéric Oudéa.
- PRESS RELEASE: ANNUAL GENERAL MEETING OF APRIL 29, 2026 - BELÉN GARIJO APPOINTED AS DIRECTOR AND CHIEF EXECUTIVE OFFICER OF SANOFI
Apr 29, 2026
ANNUAL GENERAL MEETING OF APRIL 29, 2026 BELÉN GARIJO APPOINTED AS DIRECTOR AND CHIEF EXECUTIVE OFFICER OF SANOFI PARIS, APRIL 29, 2026. SANOFI'S MIXED GENERAL MEETING OF SHAREHOLDERS CONVENED ON APRIL 29, 2026, UNDER THE CHAIRMANSHIP OF FRÉDÉRIC OUDÉA.
- Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%
Apr 28, 2026 · marketbeat.com
Several stocks with market capitalizations above $100 billion just made notable dividend announcements. These names are among the largest in their respective industries, and despite widely differing performance, continue to make good on their commitments to return more capital to shareholders.
- 3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery
Apr 25, 2026 · fool.com
Some shareholders are waiting for healthcare stocks to rebound. As they wait, some companies pay out dividends with meaningful yields that make that waiting easier.